Skip to main content
Erschienen in: Journal of Hematology & Oncology 1/2009

Open Access 01.12.2009 | Letter to the Editor

Multiple Myeloma Involving Skin and Pulmonary Parenchyma after Autologous Stem Cell Transplantation

verfasst von: Yuan Yuan, Rosemary Wieczorek, David L Green, Perry Cook, Harold Ballard, David J Araten

Erschienen in: Journal of Hematology & Oncology | Ausgabe 1/2009

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Pulmonary involvement and skin involvement are rare complications of plasma cell neoplasms. Here we describe what may be the first reported case of a patient with relapse in both of these sites following autologous peripheral blood stem cell transplantation.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1756-8722-2-48) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors were involved in the provision of clinical care of the patient and the collection of data and the review of the manuscript. RW performed immunohistochemical analysis. YY drafted the manuscript and reviewed the literature, as did DA, who performed the final edits.

Text

We report a 58-year-old man with diffuse pulmonary parenchymal plasma cell infiltration and skin nodules. Five years previously he had been treated successfully with VAD (vincristine, adriamycin and dexamethasone) chemotherapy and an autologous peripheral blood stem cell transplant for multiple myeloma. Four years later he relapsed with anemia, hypercalcemia, and an IgG of 6170 mg/dl. Skeletal survey showed no lytic lesions, the marrow was 30% infiltrated by plasma cells with a t(11;14)(q13;q32) and a del 13q14.3 abnormality. The paraprotein level transiently responded to thalidomide-dexamethasone, but he in turn developed hyperammonemia, which responded to the addition of bortezomib and liposomal pegylated doxorubicin to the regimen.
During the 3rd cycle of this regimen, subcutaneous nodules appeared on all four extremities, and a needle aspirate revealed plasma cells (figure 1A, B). The WBC rose to > 40,000/cmm with 50% circulating plasma cells. He developed dyspnea and cough, and CT revealed peri-bronchial thickening and patchy opacities diffusely (figure 1C). Bronchoalveolar lavage (BAL) demonstrated kappa restricted plasma cells (Figure 1D, E). He soon after expired, concurrent with a rise in the ammonia level.

Discussion

In plasma cell neoplasms, pulmonary complications are common, but infection is the most common cause. In a series of 958 patients with myeloma, 10% had pulmonary findings, but in only 1 case was plasma cell involvement demonstrated histologically, and the clinical course was suggestive of plasma cell involvement in only 3 other cases [1]. In the literature, there are additional cases of pulmonary involvement: some of these had advanced or treatment-refractory disease, like our patient [24], whereas in several cases, the lung was the initial site of presentation [58]. Likewise, skin involvement is rare, but this too has been reported [9, 10]. We believe that this is the first case patient reported to have both sites of involvement as a complication of relapsed disease after autologous stem cell transplantation. The presence of circulating plasma cells and hyperammonemia are both known to be indicators of advanced disease. Plasma cell neoplasm should be kept in the differential diagnosis of any pulmonary infiltrate not responding to antibiotics or as a possible cause of skin nodules in a patient with a history of myeloma, plasmacytoma, or MGUS.
The Institutional IRB approved the submission of this manuscript, which was considered by the editors to be a proxy for the patient's informed consent for the publication of the manuscript and accompanying images, in light of the fact that the patient had expired. A copy of the written documentation of this is available for review by the Editor-in-Chief of this journal.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors were involved in the provision of clinical care of the patient and the collection of data and the review of the manuscript. RW performed immunohistochemical analysis. YY drafted the manuscript and reviewed the literature, as did DA, who performed the final edits.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Anhänge

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.
Literatur
1.
Zurück zum Zitat Kintzer J, Rosenow E, Kyle R: Thoracic and Pulmonary Abnormalities in Multiple Myeloma. Archives of Internal Medicine. 1978, 138: 727-730. 10.1001/archinte.138.5.727.CrossRefPubMed Kintzer J, Rosenow E, Kyle R: Thoracic and Pulmonary Abnormalities in Multiple Myeloma. Archives of Internal Medicine. 1978, 138: 727-730. 10.1001/archinte.138.5.727.CrossRefPubMed
2.
Zurück zum Zitat Chejfec G, Natarelli J, Gould V: Myeloma lung: a previously unreported complication of multiple myeloma. Human Pathology. 1983, 14: 558-561. 10.1016/S0046-8177(83)80008-2.CrossRefPubMed Chejfec G, Natarelli J, Gould V: Myeloma lung: a previously unreported complication of multiple myeloma. Human Pathology. 1983, 14: 558-561. 10.1016/S0046-8177(83)80008-2.CrossRefPubMed
3.
Zurück zum Zitat Schelle M, Schreiber C, Florschutz A, Kachel R, Schreiber J: Pulmonary and pleural manifestations of multiple myeloma. Pneumologie. 2006, 60: 743-748. 10.1055/s-2006-944275.CrossRefPubMed Schelle M, Schreiber C, Florschutz A, Kachel R, Schreiber J: Pulmonary and pleural manifestations of multiple myeloma. Pneumologie. 2006, 60: 743-748. 10.1055/s-2006-944275.CrossRefPubMed
4.
Zurück zum Zitat Yokote T, Akioka T, Miyamoto H, Oka S, Hara S, Yamano T, Takasu T, Tsuji M, Hanafusa T: Pulmonary parenchymal infiltrates in a patient with CD20-positive multiple myeloma. European Journal of Haematology. 74: 61-65. 10.1111/j.1600-0609.2004.00326.x. Yokote T, Akioka T, Miyamoto H, Oka S, Hara S, Yamano T, Takasu T, Tsuji M, Hanafusa T: Pulmonary parenchymal infiltrates in a patient with CD20-positive multiple myeloma. European Journal of Haematology. 74: 61-65. 10.1111/j.1600-0609.2004.00326.x.
6.
Zurück zum Zitat Gabriel S: Multiple myeloma presenting as pulmonary infiltration. Dis Chest. 1965, 47: 123-136. 10.1378/chest.47.1.123.CrossRefPubMed Gabriel S: Multiple myeloma presenting as pulmonary infiltration. Dis Chest. 1965, 47: 123-136. 10.1378/chest.47.1.123.CrossRefPubMed
7.
Zurück zum Zitat Gozdziuk K, Kedra M, Ryojad P, Sagam D: A rare case of solitary plasmacytoma mimicking a primary lung tumor. Annals Thoracic Surg. 2009, 87: 25-26. 10.1016/j.athoracsur.2008.11.066.CrossRef Gozdziuk K, Kedra M, Ryojad P, Sagam D: A rare case of solitary plasmacytoma mimicking a primary lung tumor. Annals Thoracic Surg. 2009, 87: 25-26. 10.1016/j.athoracsur.2008.11.066.CrossRef
8.
Zurück zum Zitat Kamble R, Rosenzweig T: Diffuse pulmonary parenchymal involvement in multiple myeloma: antemortem diagnosis. International Journal of Hematology. 2006, 83: 259-261. 10.1532/IJH97.05002.CrossRefPubMed Kamble R, Rosenzweig T: Diffuse pulmonary parenchymal involvement in multiple myeloma: antemortem diagnosis. International Journal of Hematology. 2006, 83: 259-261. 10.1532/IJH97.05002.CrossRefPubMed
9.
Zurück zum Zitat Gambichler T, Othlinghaus N, Stucker M, Altmeyer P, AKCaE : Dermatology Cutaneous giant plasmacytoma associated with monoclonal gammopathy of unknown significance. Clinical and Experimental Dermatology. 2009, 34: 417-418. 10.1111/j.1365-2230.2008.02956.x.CrossRefPubMed Gambichler T, Othlinghaus N, Stucker M, Altmeyer P, AKCaE : Dermatology Cutaneous giant plasmacytoma associated with monoclonal gammopathy of unknown significance. Clinical and Experimental Dermatology. 2009, 34: 417-418. 10.1111/j.1365-2230.2008.02956.x.CrossRefPubMed
10.
Zurück zum Zitat Walzer R, Shapiro L: Multiple Myeloma with Cutaneous Involvement. Dermatologica. 1967, 134: 449-454. 10.1159/000254288.CrossRefPubMed Walzer R, Shapiro L: Multiple Myeloma with Cutaneous Involvement. Dermatologica. 1967, 134: 449-454. 10.1159/000254288.CrossRefPubMed
Metadaten
Titel
Multiple Myeloma Involving Skin and Pulmonary Parenchyma after Autologous Stem Cell Transplantation
verfasst von
Yuan Yuan
Rosemary Wieczorek
David L Green
Perry Cook
Harold Ballard
David J Araten
Publikationsdatum
01.12.2009
Verlag
BioMed Central
Erschienen in
Journal of Hematology & Oncology / Ausgabe 1/2009
Elektronische ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-2-48

Weitere Artikel der Ausgabe 1/2009

Journal of Hematology & Oncology 1/2009 Zur Ausgabe

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.